← Leaderboards
Heather Lynn Gardner
Tufts University Boston
$878,760
Attributed
$878,760
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $250K · FY2020–24$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$878,760 · 2
By mechanism
K01$631,260 · 1
R03$247,500 · 1
Top collaborators
No co-investigators on record.
Most similar at Tufts University Boston
Same institution · by research overlap
- Tija C. Jacob$3,131,704
- Jillian M Richmond$1,328,254
- Mengxi Du$622,473
- Sheldon Greenfield$2,758,063
Others in their field
Other Emerging Leaders on “Canis Familiaris”
- Xinhua Li · Nano Terra, Inc.$23,898,883
- John Otridge · Leidos Biomedical Research, Inc.$8,845,576
- James N Campbell · Centrexion Therapeutics Corporation$8,662,635
- Christian Arthur Heidbreder · Indivior, Inc.$8,483,680
- Nikej Shah · Nirsum Laboratories, Inc.$7,722,108
- Judith A Kelleher-Andersson · Neuronascent, Inc.$7,074,883
Research focus
Canis FamiliarisScientistResistancePrimary NeoplasmTumorVariantDesignMutationNeoplastic CellOsteosarcomaSkillsSomatic MutationAnimal Disease ModelsTumor MicroenvironmentAnimal ModelCancer CellGenomicsGenomeNeoplasm MetastasisCancer GenomeCellsGene Expression ProfileBisulfite SequencingChromatin Interaction Analysis By Paired-End Tag Sequencing
Grant awards (7)
Elucidating the therapeutic utility of targeting metabolic dependencies in osteosarcoma$126,252
K01 · FY2024 · OD · contact PI
Optimizing blood biopsy in cancers with low mutation burden and high structural complexity$123,750
R03 · FY2024 · OD · contact PI
Elucidating the therapeutic utility of targeting metabolic dependencies in osteosarcoma$126,252
K01 · FY2023 · OD · contact PI
Optimizing blood biopsy in cancers with low mutation burden and high structural complexity$123,750
R03 · FY2023 · OD · contact PI
Elucidating the therapeutic utility of targeting metabolic dependencies in osteosarcoma$126,252
K01 · FY2022 · OD · contact PI
Elucidating the therapeutic utility of targeting metabolic dependencies in osteosarcoma$126,252
K01 · FY2021 · OD · contact PI
Elucidating the therapeutic utility of targeting metabolic dependencies in osteosarcoma$126,252
K01 · FY2020 · OD · contact PI